Arena Pharmaceuticals - Stock Price History | ARNA

Historical daily share price chart and data for Arena Pharmaceuticals since 2021 adjusted for splits. The latest closing stock price for Arena Pharmaceuticals as of October 27, 2021 is 55.50.
  • The all-time high Arena Pharmaceuticals stock closing price was 462.50 on August 31, 2000.
  • The Arena Pharmaceuticals 52-week high stock price is 90.19, which is 62.5% above the current share price.
  • The Arena Pharmaceuticals 52-week low stock price is 45.50, which is 18% below the current share price.
  • The average Arena Pharmaceuticals stock price for the last 52 weeks is 67.39.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Arena Pharmaceuticals Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 60.7632 46.2400 87.7100 34.8300 76.8300 69.15%
2019 50.3058 40.2200 63.3300 39.5400 45.4200 16.61%
2018 40.4410 36.2100 49.6300 30.8900 38.9500 14.66%
2017 20.0076 14.7000 34.6600 11.5000 33.9700 139.23%
2016 16.5036 18.3000 21.5000 13.5000 14.2000 -25.26%
2015 35.8980 35.9000 60.5000 17.0000 19.0000 -45.24%
2014 53.4490 58.7000 77.2000 33.7000 34.7000 -40.68%
2013 71.6921 90.1000 108.1000 40.8000 58.5000 -35.14%
2012 62.7528 19.2000 118.1000 15.6000 90.2000 382.35%
2011 15.0441 17.7000 21.9000 12.3000 18.7000 8.72%
2010 33.1954 35.3000 79.5000 12.7000 17.2000 -51.55%
2009 40.8730 42.5000 71.5000 23.2000 35.5000 -14.87%
2008 55.5846 76.7000 84.8000 29.3000 41.7000 -46.74%
2007 116.7563 127.2000 145.7000 78.3000 78.3000 -39.35%
2006 140.1357 154.5000 204.3000 92.3000 129.1000 -9.15%
2005 78.8363 65.0000 144.9000 49.2000 142.1000 112.09%
2004 54.1374 64.1000 70.0000 35.7000 67.0000 8.06%
2003 69.0024 66.5000 85.4000 61.4900 62.0000 -4.76%
2002 78.8792 121.7000 123.2000 53.6000 65.1000 -45.89%
2001 191.0484 141.3000 354.7000 90.0000 120.3000 -22.39%
2000 305.2417 250.0000 462.5000 140.6000 155.0000 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.478B $0.000B
Arena Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel drugs that target G protein-coupled receptors, or GPCRs, to address unmet medical needs. BELVIQ (lorcaserin HCl), their internally discovered drug for chronic weight management, is their first and only drug approved by any regulatory agency for marketing. BELVIQ was approved by the US Food and Drug Administration, or FDA, for marketing in the United States, and was made available by prescription in June 2013 to adults who are overweight with a comorbidity or obese. They are exploring BELVIQ for possible new indications, using different formulations, and in combination with other drugs.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86